Novel GAA sequence variant c.1211 A > G reduces enzyme activity but not protein expression in infantile and adult onset Pompe disease

被引:4
作者
Nilsson, M. I. [1 ]
Kroos, M. A. [3 ]
Reuser, A. J. [3 ,4 ]
Hatcher, E. [1 ]
Akhtar, M. [1 ]
McCready, M. E. [2 ]
Tarnopolsky, M. A. [1 ]
机构
[1] McMaster Univ, Dept Pediat, Med Ctr, Hamilton, ON L8 3Z5, Canada
[2] McMaster Univ, Dept Pathol & Mol Med, Med Ctr, Hamilton, ON L8 3Z5, Canada
[3] Erasmus MC Univ, Med Ctr, Dept Clin Genet & Pediat, Rotterdam, Netherlands
[4] Erasmus MC Univ, Med Ctr, Ctr Lysosomal & Metab Dis, Rotterdam, Netherlands
关键词
Muscle; Acid alpha-glucosidase; Glycogen storage disease type 2; Acid maltase; Enzyme replacement therapy; CLINICAL SPECTRUM; DESCRIBE;
D O I
10.1016/j.gene.2013.12.033
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Pompe disease is a clinically and genetically heterogeneous autosomal recessive disorder caused by lysosomal acid alpha-glucosidase (GAA) deficiency. We report on two affected members of a non-consanguineous Caucasian family, including a classical infantile-onset patient with severe cardiomyopathy (10) and his paternal grandmother with the adult-onset (AO) form. Two compound heterozygous sequence variants of the GM gene were identified in each patient by mutation analyses (IO = c.1211A > G and c.1798C > T; AO = c.1211A > G and c.692 + 5G > T). For this study, the biochemical phenotype resulting from the missense mutation c.1211A > G in exon 8, which converts a highly conserved aspartate to glycine (p.Asp404Gly), was of specific interest because it had not been reported previously. Western blotting revealed a robust expression of all GAA isoforms in quadriceps muscle of both patients (fully CRIM positive), while enzymatic activity was 3.6% (10) and 6.6% (AO) of normal controls. To further validate these findings, the c.1211A > G sequence variant was introduced in wild type GM cDNA and over-expressed in HEK293T cells. Site-directed mutagenesis analyses confirmed that the mutation does not affect processing or expression of GAA protein, but rather impairs enzyme function. Similar results were reported for c.1798C > T (p.Arg600Cys), which further supports the biochemical phenotype observed in ID. The third mutation (c.692 + 5G > T, in intron 3) was predicted to affect normal splicing of the GAA mRNA, and qPCR indeed verified a 4-fold lower mRNA expression in AO. It is concluded that the novel sequence variant c.1211A > G results in full CRIM but significantly lower GAA activity, which in combination with c.1798C > T leads to infantile-onset Pompe disease. We surmise that the difference in disease severity between the two family members in this study is due to a milder effect of the intronic mutation c.692 + 5G > T (vs. c.1798C > T) on phenotype, partially preserving GM activity and delaying onset in the proband (paternal grandmother). (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:41 / 45
页数:5
相关论文
共 13 条
[1]   Two clinical forms of glycogen-storage disease type II in two generations of the same family [J].
Amartino, H ;
Painceira, D ;
Pomponio, RJ ;
Niizawa, G ;
Sabio Paz, V ;
Blanco, M ;
Chamoles, N .
CLINICAL GENETICS, 2006, 69 (02) :187-188
[2]   Response to the letter "How to describe the clinical spectrum in Pompe disease?" [J].
Beckemeyer, Alexandra A. ;
Mendelsohn, Nancy J. ;
Kishnani, Priya S. .
AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2013, 161A (02) :401-402
[3]   How to describe the clinical spectrum in Pompe disease? [J].
Gungor, Deniz ;
Reuser, Arnold J. J. .
AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2013, 161A (02) :399-400
[4]  
Hoefsloot L, 1990, AM J HUM GENET, V46
[5]  
Kishnani P., NEUROMUSCUL DISORD, V22, P852
[6]  
Kroos M, 2012, AM J MED GENET C, V160C, P59, DOI [10.1002/ajmc.31318, 10.1002/ajmg.c.31318]
[7]   Dysferlin aggregation in limb-girdle muscular dystrophy type 2B/myoshi myopathy necessitates mutational screen for diagnosis [J].
Nilsson, Mats I. ;
Laureano, Marissa L. ;
Saeed, Munim ;
Tarnopolsky, Mark A. .
MUSCLE & NERVE, 2013, 47 (05) :740-747
[8]   Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease [J].
Nilsson, Mats I. ;
Samjoo, Imtiaz A. ;
Hettinga, Bart P. ;
Koeberl, Dwight D. ;
Zhang, Haoyue ;
Hawke, Thomas J. ;
Nissar, Aliyah A. ;
Ali, Tahir ;
Brandt, Linda ;
Ansari, Mohammad U. ;
Hazari, Hassan ;
Patel, Neha ;
Amon, Jaihoon ;
Tarnopolsky, Mark A. .
MOLECULAR GENETICS AND METABOLISM, 2012, 107 (03) :469-479
[9]  
REUSER AJJ, 1995, MUSCLE NERVE, pS61
[10]   Structural modeling of mutant α-glucosidases resulting in a processing/transport defect in Pompe disease [J].
Sugawara, Kanako ;
Saito, Seiji ;
Sekijima, Masakazu ;
Ohno, Kazuki ;
Tajima, Youichi ;
Kroos, Marian A. ;
Reuser, Arnold J. J. ;
Sakuraba, Hitoshi .
JOURNAL OF HUMAN GENETICS, 2009, 54 (06) :324-330